Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted MyelomaMarco Ladetto, Antonio Palumbo, Francesco Pisani et al.|Journal of Clinical Oncology|2010Cited by 268
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survivalSimone Ferrero, Antonio Palumbo, Marco Ladetto et al.|Leukemia|2014Cited by 83
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated resultsFrancesca Gay, Antonio Palumbo, Valeria Magarotto et al.|Blood|2013Cited by 82
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapyFederica Cavallo, Antonio Palumbo, Giuseppe Milone et al.|Leukemia|2011Cited by 63
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomibManuela Gambella, Antonio Palumbo, Alberto Rocci et al.|Haematologica|2014Cited by 56